latest news releases from the newsroom
Alchemy Ventures Ltd.
Alchemy Ventures Ltd.: Geological and analytical programs on the Helmer-Bovill project confirms high-quality feldspar and quartz products and significant tonnage potential
RICHMOND, British Columbia, April 8, 2003 (PRIMEZONE) -- Alchemy Ventures Ltd. (TSX Venture Exchange:ALY) has recently completed another stage of its ongoing project evaluation of the Helmer-Bovill feldspar-kaolin-quartz project located in Latah County, Idaho. This work program integrated geologic, petrographic, geochemical and metallurgical studies to develop a mineral deposit model that will be the basis for further work. Field mapping, in conjunction with the core-hole data from the previous drilling program, provide conceptual limits to the Helmer-Bovill mineral deposit model while the petrographic, electron microprobe, and geochemical analyses demonstrate that high quality feldspar and quartz products can be produced. Further, analytical and metallurgical results received to date indicate that a very high purity quartz product can be produced. This integrated program has identified two areas that are the most prospective for development of economically mineable deposits of feldspar, kaolin, and quartz.
Banyan Announces Creation of Subsidiary -- Banyan Financial Services, Inc.
LOS ANGELES, April 8, 2003 (PRIMEZONE) -- Banyan Corporation (OTCBB:BANY) is pleased to announce the creation of Banyan Financial Services, Inc. (Banyan Financial), a wholly-owned subsidiary, to provide practice finance solutions to the Chiropractic, Medical, Dental and Healthcare communities. Initially created to assist Chiropractic USA franchisees and the Chiropractic community by offering affordable practice finance options, Banyan Financial will serve other healthcare professionals and the healthcare services community as well.
Kinnevik acquires shares in Norway's P4 radio
STOCKHOLM, April 8, 2003 (PRIMEZONE) -- Industriforvaltnings AB Kinnevik today announced that it has acquired 4,018,620 shares in Radio P4 Hele Norge ASA from Centennial ASA and Endre Rosjo. Kinnevik now owns 4,026,820 P4 shares, representing 12.5% of the issued and outstanding share capital. P4 is Norway's only national commercial radio network.
Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Announces Filing of Class Action Lawsuit Against Cerner Corp. -- CERN
NEW YORK, April 8, 2003 (PRIMEZONE) -- Notice is hereby given that a class action lawsuit was commenced in the United States District Court for the Western District of Missouri on behalf of all purchasers of Cerner Corp. ("Cerner" or the "Company") (Nasdaq:CERN) securities between October 16, 2002 through April 2, 2003, inclusive (the "Class Period"). A copy of the complaint filed in this action can be viewed on the firm's website at www.faruqilaw.com
Landskroner Grieco Merriman, LLC
Landskroner - Grieco, Ltd. Files Class Action Lawsuit on Behalf of Purchasers of Securities of AFC Enterprises -- AFCE
CLEVELAND, April 8, 2003 (PRIMEZONE) -- Landskroner - Grieco, Ltd. announces that it has filed a class action lawsuit in the United States District Court for the Northern District of Georgia on behalf of purchasers of securities of AFC Enterprises, Inc., ("AFC" or the "Company") (Nasdaq:AFCE) between March 2, 2001 and March 24, 2003 (the "Class Period"). A copy of the complaint will be emailed to you upon request or is available from the court. The suit is brought against AFC, Frank J. Bellati (CEO), and Gerald J. Wilkins (CFO).
Pharmexa Submits Application to Start Clinical Phase I Trial in Breast Cancer
HORSHOLM, Denmark, April 8, 2003 (PRIMEZONE) -- Pharmexa (Other OTC:PMXAY) has submitted an application to start a clinical phase I trial with the company's HER-2 Protein AutoVac(TM) product to the US health authorities. The trial, which will take place in two US breast cancer centers, is planned to enroll approximately 10 patients with advanced HER-2 positive breast cancer. The HER-2 protein is found in up to 30% of breast cancers and is among other things involved in cancer cell division and growth. Following approval, it is expected that the trial can be initiated in May 2003 and that results will be available by the end of the year.